

7 pits

10/520397

10 Rec'd PCT/PTO 05 JAN 2005  
PCT/FR2003/002117

WO 2004/008144

METHOD CAPABLE OF BEING AUTOMATED FOR DETECTION OF  
PrP<sup>res</sup> AND USES THEREOF

The present invention relates to a sensitive,  
5 rapid and simple method capable of being entirely  
automated for detecting PrP<sup>res</sup> in a biological sample  
and also to uses thereof.

Transmissible subacute spongiform  
encephalopathies (TSSEs) are caused by nonconventional  
10 transmissible agents (NCTAs), also called prions, the  
precise nature of which remains disputed to date. TSSEs  
essentially comprise Creutzfeldt-Jakob disease in  
humans (CJD), scrapie in sheep and goats, and bovine  
spongiform encephalopathy (BSE) in bovines; other  
15 encephalopathies have been demonstrated in Felidae, in  
mink or in certain wild ruminants such as stags.

These diseases progress to be constantly fatal  
and, at the current time, no effective treatment  
exists.

20 In TSSEs, the accumulation of a host protein,  
PrP (or prion protein), in an abnormal form (PrP<sup>res</sup>), is  
commonly observed, during the clinical phase of the  
disease, mainly in the central nervous system in the  
form of amorphous aggregates or of amyloid plaques.  
25 PrP<sup>res</sup> copurifies with the infectiousness and its  
accumulation precedes the appearance of the  
histological lesions. In vitro, it is toxic for neurone  
cultures.

The two isoforms of PrP have the same amino  
30 acid sequence, but differ in their secondary structure:  
PrP<sup>res</sup> has a significantly higher content of  $\beta$ -pleated  
sheets, whereas normal PrP (PrP<sup>sens</sup>) has a greater  
percentage of  $\alpha$ -helices.

The infectious isoform PrP<sup>res</sup> is capable of  
35 converting the normal protein, i.e. PrP<sup>sens</sup>, to an  
infectious protein.

Two biochemical properties generally make it  
possible to distinguish these two isoforms:

- PrP<sup>res</sup> is partially resistant to proteases, in

Best Available Copy

- 2 -

particular to proteinase K (PK), which results in cleavage of its N-terminal end. After the action of PK, PrP<sup>res</sup> is often called PrP27-30 because of the apparent molecular weight of the diglycosylated form; it is generally accepted that the PrP<sup>res</sup> cleavage site is located between amino acids 89 and 90 (Prusiner et al, Cell, 1984) for the usual strains;

- PrP<sup>res</sup> is insoluble and aggregates in nonionic detergents, such as Triton X100 or Triton 114, forming amyloid fibers (scrapie associated fibrils, SAFs).

The normal form of the prion protein (PrP<sup>sens</sup>) is, in principle, completely degraded by proteases and is entirely soluble in the presence of nonionic detergents.

To detect the presence of the infectious agent, most of the methods are based on a selective detection of the abnormal PrP (PrP<sup>res</sup>), associated with the infectious agent, by taking advantage of its partial resistance to proteases and of its aggregation properties.

However, although PrP<sup>res</sup> and PrP<sup>sens</sup> differ in terms of their physical properties, it is in fact very difficult to develop immunoassays which make it possible to reliably differentiate the two isoforms of PrP, in particular due to the lack of PrP<sup>res</sup>-specific antibodies. In fact, to date, the only antibodies available recognize either PrP<sup>sens</sup> or the two forms of PrP (sens or res) after they have undergone a denaturation step. It is for this reason that, in virtually all the immunoassays dedicated to the diagnosis of TSSEs, there is a denaturation step so as to allow immunodetection of PrP<sup>res</sup>.

The five major methods conventionally used for diagnosing TSSEs are:

1. histopathology, which is aimed at detecting, essentially in central nervous tissues, the lesions characteristic of TSSEs (spongiosis, vacuolization, astrogliosis, PrP amyloid plaques); it remains a reference method for confirming a clinical diagnosis.

- 3 -

It is very specific since it makes it possible to directly observe the marks of the disease. However, it is now known that it is less sensitive than other techniques. This method has the drawback of not  
5 allowing a preclinical diagnosis, insofar as the anatomical lesions appear late in the history of the disease. In addition, it is not at all suitable for an analysis carried out in large series.

2. immunohistory chemistry, which makes it  
10 possible to detect the amyloid plaques or the deposits of PrP<sup>res</sup> using PrP-specific antibodies. The sensitivity of the observation under the microscope can, in fact, be significantly increased by virtue of this approach. These techniques are certainly among the methods that  
15 are the most sensitive today, but they remain laborious and are especially used as confirmation methods.

3. detection of the amyloid fibers by electron microscopy. This method has the drawback of being relatively insensitive and laborious to implement. It  
20 has, today, been virtually abandoned.

4. bioassays, which are aimed at identifying the infectious nature of a sample. In fact, the most sensitive method for diagnosing TSSEs is, unquestionably, experimental infection in laboratory  
25 animals. This method consists in injecting an animal with a homogenate prepared from the tissue studied and in monitoring the appearance of the clinical signs. The development of this experimental disease is confirmed using conventional techniques (histology,  
30 immunohistology, Western blotting). For obvious practical reasons, these experiments are generally carried out on rodents (mice, hamsters) but, in certain extreme cases, experimental infections have been carried out with members of the ovine race or bovines.  
35 The efficiency of the experimental transmission depends on many factors, and in particular: on the species barrier, on the amount of transmissible agent inoculated, on the strain of prion, on the sensitivity to the recipient species and on the route of

- 4 -

inoculation. The most efficient route is the intracranial route, and then the intravenous route (10 times less efficient). The least efficient route is the oral route (100 000 times less efficient than the intracranial route). Thus, the most sensitive means for detecting the transmissible agent responsible for BSE is intracranial injection in bovines. The main drawbacks of these methods are, firstly, their laborious nature and, secondly, their duration. In fact, it takes between 300 and 700 days to carry out an experimental infection test in mice and between 3 and 10 years in bovines. The availability of transgenic mice expressing the same PrP as that of the donor species will make it possible to shorten these periods, but, in all cases, these tests will last at least three months.

5. Western blotting methods, which are based on the immunodetection of PrP<sup>res</sup> in a tissue extract, after treatment of the extract with a protease (PF, for example), so as to destroy the normal isoform of PrP (PrP<sup>sens</sup>), separation of the proteins of the extract by electrophoresis, transfer onto a polymer membrane, and detection with a specific antibody that recognizes PrP (O. Schaller et al., Acta Neuropathol (Berl), 1999, 98, 437-443). For the reasons explained above, the digestion with a protease is necessary insofar as, in order to perform a Western blotting analysis, the protein is denatured, which implies that there no longer exists any difference between the normal form (PrP<sup>sens</sup>) and the pathological form (PrP<sup>res</sup>) of the prion protein. Digestion with PK overcomes this disadvantage since PrP<sup>sens</sup> is completely digested, whereas PrP<sup>res</sup> is relatively unmodified. The specificity of this approach comes, inter alia, from the fact that, under the action of proteinase K, the molecular weight of PrP<sup>res</sup> is modified in a characteristic manner due to the partial degradation of the N-terminal portion of the protein. Its sensitivity is of the same order of magnitude as that of immunohistology. The main drawback of this

- 5 -

technique is linked to the difficulty in carrying it out, to the duration of the analysis (> 8 hours) and to the fact that it is impossible to automate it.

More recently, ELISA-type assays have been  
5 described. Among these, some involve treatment of the tissue extracts with a protease; mention may be made of:

- that described by Serban et al. (Neurology, 1990, 40, 110), who had developed an assay for  
10 detecting PrP<sup>res</sup> which includes immobilization of the proteins on a nitrocellulose membrane, followed by protease digestion, denaturation, and immunodetection with monoclonal antibodies;

- that described by Oesch et al. (Biochemistry, 1994, 33, 5926-5931), who have proposed, in order to  
15 quantify the amount of PrP<sup>res</sup>, an immunofiltration assay for the purification of PrP<sup>res</sup> (ELIFA or enzyme-linked immunofiltration assay);

- that described by Gratwohl et al., 1997, who  
20 propose an ELISA-type assay. After treatment of the samples with proteinase K and purification of PrP<sup>res</sup> by centrifugation, said PrP<sup>res</sup> is adsorbed onto microtitration plates and detected by means of rabbit polyclonal antibodies.

25 None of the abovementioned methods is truly suited to a high throughput screening and cannot be suitable for automation. After the first "mad cow crisis" in 1996 and the possible transmission of this disease to humans being taken into consideration, it  
30 was felt that there was a need to develop new diagnostic approaches that were simpler and faster. These methods will have to make it possible to either carry out epidemiological studies on a large scale, in order to evaluate more precisely the characteristics of  
35 the epizootic, or to systematically test, in the abattoir for example, all animals before they enter into the food chain or the industrial circuits. Thus, a new generation of "fast" diagnostic tests developed, which tests are all based on the immunodetection of

- 6 -

PrP<sup>res</sup>.

In May 1998, European Commission Directorate General XXIV (consumer policy and consumer health protection) put out a worldwide invitation to tender, intended to take an inventory of the techniques capable of performing a high throughput of BSE screening and liable to rapidly give rise to an industrial development. At the end of this invitation to tender (June 1998), four tests were selected. Three of them were developed by industrial companies: Enfer Technology Ltd (Ireland) (international PCT applications WO 98/35236, in the name of Enfer Technology Ltd, and WO 93/11155, in the name of Proteus Molecular Design Limited), Prionics (Switzerland) (international PCT application WO 99/15651) and E.G. & G. Wallac (Great Britain) (international application WO 00/29850), and the fourth was developed in two laboratories of the CEA [Atomic Energy Commission] (France). The aim of these four tests is to detect the presence of PrP<sup>res</sup> in the brain of animals. They all involve treatment of the brain extracts with proteinase K in order to destroy PrP<sup>sens</sup> and to allow selective measurement of PrP<sup>res</sup>. The Prionics test uses the Western blotting technique in an industrialized form, whereas the tests developed by Enfer Technology and Wallac are immunoenzyme assays of the ELISA type. The test developed by the CEA involves, first, selective purification of PrP<sup>res</sup>, which is then assayed by means of a sandwich assay using two monoclonal antibodies (two-site immunoenzymetric assay). This study showed that three of the tests evaluated (Prionics, Enfer and CEA) had an excellent ability to specifically detect bovines that were at the clinical stage of the disease. Moreover, the test developed by the CEA showed that it was significantly more sensitive than that of the competitors, due in particular to the PrP<sup>res</sup> purification/concentration step (Moynagh et al., Nature, 1999, 400, 105; <http://europa.eu.int/comm/dg24/health/>).

- 7 -

Thus, the Applicant has proposed a test for quantitatively detecting PrP<sup>res</sup>, which comprises a purification step which results in a significantly more sensitive detection; this test is in particular  
5 described in international PCT application WO 99/41280 and in a preliminary report from the European Commission Directorate General XXIV (consumer policy and consumer health protection; <http://europa.eu.int/comm/dg24/health/>); it has also  
10 proposed, in international PCT application WO 01/35104, a diagnostic method which, besides the possibility of purification mentioned above, uses treatment of the biological sample with a protease, so as to completely degrade PrP<sup>sens</sup> under the conditions where all or some  
15 of the repeat octapeptide units of PrP<sup>res</sup> are conserved; this makes it possible to detect PrP<sup>res</sup> using a high-affinity anti-octapeptide antibody. This method is very sensitive and very specific; however, the purification/concentration method comprises several  
20 steps, and in particular a centrifugation step, which prohibits any complete automation of the test.

Since 1999, these rapid tests have shown their use in the context of epidemiological studies relating to populations at risk (dead animals, destroyed as an  
25 emergency or put down because of disease). Since the beginning of 2001, they have been used on a very large scale, in order to test all bovines over the age of 24 or 30 months which enter into the food chain (8.5 million tests performed in 2001).

30 Today, the priority in the field of prion-disease diagnosis is the development of an ante-mortem and preclinical test for variant Creutzfeldt-Jakob disease. The objective is first to make blood transfusion safe and then to achieve early detection of  
35 individuals suffering from this disease in order to be able to envision setting up a treatment (which does not exist at this time) before the phase of neuroinvasion and the appearance of the first irreversible clinical signs. This necessarily implies the development of a

- 8 -

test on a blood sample or urine sample, the only biological fluids that can readily be sampled noninvasively. This objective appears to be achievable since some publications refer to the presence of infectious prions or of PrP<sup>res</sup> in the blood (Brown et al., Transfusion, 1999, 39, 1169-1178; Houston et al. The Lancet, 2000, 356, 999-1000; Schmerr et al., J. Chromat. A., 1999, 853, 207-214) or in the urine (Shaked et al., J. Biol. Chem., 2001, 276, 31479-31482). However, the analysis of this type of sample poses analytical problems that are much more difficult to solve than those encountered in analyzing tissues known to replicate and accumulate PrP<sup>res</sup> (brains, lymphoid tissues). In fact, the data available on the physiopathology of TSSEs show that, in any event, PrP<sup>res</sup> is at least 100 times less concentrated in the blood or urine than in a spleen or a brain. Furthermore, it is probable that, in these media (urine, white blood cells), the biochemical properties of PrP<sup>res</sup> are different from those observed in the tissues where it substantially accumulates. Its aggregation properties and its resistance to PK may in particular be very decreased. It is possible, for example, that the proteinase K treatments used to analyze a brain sample also destroy the traces of PrP<sup>res</sup> contained in the blood. Consequently, in order to analyze this type of sample, strategies different from those developed to date must be developed.

One of the possible options consists in using a ligand capable of specifically recognizing PrP<sup>res</sup>. This ligand, immobilized on a suitable solid support, could make it possible to concentrate PrP<sup>res</sup> in media, such as blood or urine, in which it is relatively unconcentrated. Insofar as the interaction between the ligand and PrP<sup>res</sup> is really specific, proteinase K treatment will not be necessary, nor will it be necessary to make use of the aggregation properties of PrP<sup>res</sup>.

This type of ligand has been described recently

- 9 -

by the team of Adriano Aguzzi (Fischer et al., Nature, 2000, 408, 479-483; Maissen et al., The Lancet, 2001, 357, 2026-2028) and has been the subject of an international application WO 01/23425. In that international application, in order to allow the detection of small amounts of prion, it is proposed to concentrate PrP<sup>res</sup> or its PK-digestion products by treatment of the biological sample concerned with magnetic beads carrying prion-binding sites: purified plasminogen, fibrinogen, fraction I of ammonium sulfate precipitation of serum or plasma, or fraction II of ammonium sulfate precipitation of serum or plasma. The PrP<sup>res</sup> is therefore first concentrated by incubation with magnetic beads carrying plasminogen or fibrinogen, and then detected by Western blotting analysis, ELISA, immunoprecipitation, BIACORE assay, immunocytochemical assay or histoblot assay after elution of the PrP<sup>res</sup> from the solid support. In this method, the conditions are as follows:

- sample preparation step: homogenization and centrifugation of the homogenate; it is important to use, during the first homogenization step, low concentrations of ionic detergents, followed by low-speed centrifugation (500 g for 30 minutes), whereas, in the subsequent steps, high concentrations of nonionic detergents are used; a protein concentration in the homogenate of at most 5 mg/ml is preferably obtained;

- digestion with proteinase K: preferably in the presence of 50 µg/ml of PK, at 37°C, for at least half an hour;

- conditions for incubation of the magnetic beads with the homogenate, in a nonionic buffer: approximately 1 and a half hours at ambient temperature;

- detection conditions: in order to carry out this operation, it is first of all necessary to denature the proteins attached, which results in them detaching from the magnetic beads: the procedure is

- 10 -

carried out in two stages: washing of the beads with a washing buffer comprising 2% Tween 20 and 2% NP-40 in PBS, and then addition of a loading buffer for the electrophoresis comprising 50 mM tris, pH 6.8, 2% SDS, 0.01% bromophenol blue and 10% glycerol, and heating at 95°C for 5 minutes. The denatured PrP<sup>res</sup> thus eluted from the solid support containing the plasminogen is then analyzed by means of Western blotting. In fact, since no antibody specific for PrP<sup>res</sup>, capable of detecting it when it is bound to plasminogen, exists, it is necessary to break the plasminogen/PrP<sup>res</sup> bond and therefore to denature the PrP<sup>res</sup>, so as to detect it in denatured form by another method, which implies that it is detached from the beads. Such a procedure is suitable for Western blotting analysis, but not at all suitable for ELISA-type assays that use a support such as microtitration plates or magnetic beads. In fact, the conditions used in the method described in that international application WO 01/23425 (use of SDS, in particular), due to the dissociation of the plasminogen/PrP<sup>res</sup> complex when it is denatured, means that an additional step of binding into a solid support is necessary. It should be noted, in addition, that the method described in that application does not show any ability to concentrate the PrP<sup>res</sup> contained in a large volume of sample.

Because of this, the applicant gave itself the aim of providing a specific, sensitive, simple and rapid method for detecting PrP<sup>res</sup>, which corresponds more thoroughly to the current objectives of the diagnosis of TSSEs than the detection methods of the prior art, in particular:

- in that it is easy to use, i.e. more suitable for the conditions of routine use and therefore can be entirely automated; and

- in that it is capable of purifying and concentrating PrP<sup>res</sup> without making use of its PK-resistance or aggregation properties.

A subject of the present invention is a method

- 11 -

for detecting PrP<sup>res</sup> in a biological sample, using a solid support, in particular magnetic beads or micro-titration plates, on which plasminogen is immobilized, which method is characterized in that it comprises:

5 (a) a step which consists in preparing the biological sample, which may consist of either a tissue or cell homogenate, or of serum or plasma, or of urine, during which step this sample is incubated in a buffer selected from the group consisting of:

10 (i) buffers for homogenizing the biological sample comprising (1) a buffer selected from the group consisting of buffers comprising at least one surfactant selected from the group consisting of ionic surfactants and nonionic surfactants, a glucose-  
15 containing buffer, a sucrose-based buffer and a PBS buffer and (2) optionally, a proteinase K at a final concentration of between 1 and 8 µg/ml, preferably at a final concentration of between 2 and 4 µg/ml, and

(ii) capture buffers comprising at least (1) a  
20 surfactant selected from the group consisting of ionic surfactants, and (2) optionally, a proteinase K at a final concentration of between 1 and 8 µg/ml, preferably at a final concentration of between 2 and 4 µg/ml.

25 Although, under the capture conditions selected in step (b) below, the plasminogen very preferentially recognizes PrP<sup>res</sup>, in certain situations, prior controlled treatment with PK (i.e. during step (a) for preparing the biological sample) makes it possible to  
30 eliminate the signal associated with a residual recognition of PrP<sup>sens</sup>. For this reason, it is considered that the controlled use of PK in this step is optional; moreover, in situations where it may be feared that the treatment with PK affects PrP<sup>res</sup> (for  
35 example in a blood or urine sample), this PK-treatment step can be eliminated.

It should be noted that the concentration of PK used is much lower than that used in international application WO 01/23425 (50 µg/ml) or in the other

- 12 -

tests using PK (commonly between 40 and 100  $\mu\text{g/ml}$ );

(b) a step which consists in capturing  $\text{PrP}^{\text{res}}$  on said solid support, necessarily carried out in the presence of a capture buffer as defined above, without  
5 PK, i.e. in which the surfactants are exclusively ionic surfactants, by incubation of the biological sample obtained in step (a) with said support on which plasminogen is covalently immobilized; this step  
10 comprises, if necessary, prior to the incubation, a dilution of the biological sample obtained in step (a) in said capture buffer, so as to obtain the adjustment of the protein concentration, in particular when step (a) has been carried out in a homogenizing buffer.

The optimum protein concentration in the  
15 biological sample varies according to the medium studied. In the case of a brain homogenate, it is preferable for it not to exceed approximately 2 mg/ml (corresponding to a homogenate at 2% w/v), otherwise a loss of efficiency of the capture of  $\text{PrP}^{\text{res}}$  may be  
20 observed. This limitation is probably linked to the presence in the sample of uncharacterized substances capable, themselves also, of binding to the plasminogen. It constitutes a drawback compared with other methods of concentration (for example that  
25 described in international PCT application WO 99/41280) which make it possible to treat more concentrated homogenates (homogenate at 20% w/v, i.e. approximately 20 mg/ml of protein);

(c) a step which consists of controlled  
30 denaturation of the  $\text{PrP}^{\text{res}}$  attached to said support by means of the plasminogen, comprising incubation of the  $\text{PrP}^{\text{res}}$  with a denaturing buffer comprising at least one chaotropic agent, at a temperature of between ambient temperature and 100°C.

35 This controlled denaturation step is compatible with maintenance of the plasminogen/ $\text{PrP}^{\text{res}}$  complex;

(d) a step which consists in detecting the denatured  $\text{PrP}^{\text{res}}$  attached to said support, with a  $\text{PrP}$  protein-specific antibody.

- 13 -

After capture step (b), the support to which the Prp<sup>res</sup> is possibly attached can advantageously be washed; the washing conditions, and in particular the washing buffer used, are not essential in the method according to the invention.

According to an advantageous embodiment of the method according to the invention, the ionic surfactant used in step (a) or in step (b) is selected from the group consisting of:

- anionic surfactants, such as SDS (sodium dodecyl sulfate), sarkosyl (lauroylsarcosine), sodium cholate, sodium deoxycholate (DOC) or sodium taurocholate; and
- zwitterionic surfactants such as SB 3-10 (decylsulfobetaine), SB 3-12 (dodecylsulfobetaine), SB 3-14 (tetradecylsulfobetaine), SB 3-16 (hexadecylsulfobetaine), CHAPS or deoxy-CHAPS.

According to another advantageous embodiment of the method according to the invention, the nonionic surfactant used in step (a) of the method according to the invention is selected from the group consisting of C12E8 (dodecyl octaethylene glycol), Triton X100, Triton X114, Tween 20, Tween 80, MEGA 9 (nonanoyl methyl glucamine), octylglucoside, LDAO (dodecyl dimethylamine oxide) or NP40.

According to another advantageous embodiment of the method according to the invention, the incubation time in step (a) is between 5 and 30 minutes at 37°C, preferably for 10 minutes at 37°C.

According to another advantageous embodiment of the method according to the invention, the capture buffer preferably comprises sarkosyl at a final concentration of between 0.5% and 2% (w/v), even more preferably at a final concentration of sarkosyl of 1% (w/v).

According to another advantageous embodiment of the method according to the invention, the capture buffer also comprises a salt preferably selected from alkali metal salts, preferably sodium chloride, even

- 14 -

more preferably at a concentration of between 0.15 M and 0.5 M.

According to yet another advantageous embodiment of the method according to the invention, the capture buffer also comprises a protein, and even more preferably bovine serum albumin at a concentration of 0.2 mg/ml.

According to another advantageous embodiment of the method according to the invention, the incubation time in step (b) is between 1 hour and 4 hours at ambient temperature.

According to another advantageous embodiment according to the invention, the chaotropic agent used in the controlled denaturation step (c) is selected from the group consisting of urea, a guanidine salt, such as guanidine hydrochloride or guanidine thiocyanate, and sodium thiocyanate, or a mixture thereof.

According to another advantageous embodiment of the method according to the invention, the incubation time in step (c) is between 10 and 60 minutes, preferably either for 30 minutes at 37°C with the microtitration plates or for 10 minutes at 100°C with the magnetic beads.

According to another advantageous embodiment of the method according to the invention, the tracer antibody in step (d) is a polyclonal or monoclonal antibody selected from the group consisting of SAF antibodies and anti-recombinant PrP antibodies; more precisely, the SAF antibodies, and more particularly the SAF-34, SAF-53 and SAF-61 antibodies, were obtained by immunizing mice, in which the PrP gene had been knocked out, with denatured hamster SAFs (Demart et al., Biochem. Biophys. Res. Commun., 1999, 265, 652-657). The BAR-221, BAR-224 and BAR-233 antibodies were obtained by immunizing mice, in which the PrP gene had been knocked out, with a recombinant sheep PrP. The 8G8 antibody was obtained by immunizing mice, in which the PrP gene had been knocked out, with a recombinant human PrP (Krasemann et al., J. Immunol. Methods, 1996, 199,

- 15 -

109-118 and Mol. Med., 1996, 2, 725-734).

In accordance with the invention, the solid support is advantageously selected from the group consisting of magnetic beads and microtitration plates.

5 Surprisingly, the fact that the biological sample:

- is, if necessary, homogenized in a homogenizing buffer optionally comprising PK, at very low concentrations (between 1 and 8  $\mu\text{g/ml}$ ),

10 - is incubated in a capture buffer containing, as surfactant, exclusively ionic surfactants,

- is brought into contact with a solid support, to which plasminogen is covalently attached,

15 - and then is subjected to a controlled denaturation step which also surprisingly does not result in the destruction of the  $\text{PrP}^{\text{res}}$ -plasminogen bond, allows selective attachment of  $\text{PrP}^{\text{res}}$  to the solid support and direct assaying of the  $\text{PrP}^{\text{res}}$  on the solid support, without requiring additional steps.

20 Such a method makes it possible to perform a continuous, completely automated assay, unlike the method described in international PCT application WO 99/41280 which requires a centrifugation step. Such an assay also has a sensitivity that is at least as  
25 good as that obtained with the methods using a purification step, as described in international PCT application WO 99/41280.

A subject of the present invention is also a diagnostic kit for carrying out the method as defined  
30 above, characterized in that it comprises, in combination:

- at least one homogenizing buffer as defined above,

- at least one capture buffer as defined above,

35 - at least one denaturing buffer as defined above,

- a proteinase K at a final concentration of between 1 and 8  $\mu\text{g/ml}$ , preferably at a final concentration of between 2 and 4  $\mu\text{g/ml}$ , and

- 16 -

- a solid support to which plasminogen is covalently attached.

Besides the above provisions, the invention comprises other provisions which will emerge from the following description, which refers to nonlimiting  
5 examples of the method according to the invention and also to the attached drawings in which:

- figure 1 illustrates the effect of the proteinase K concentration on the CP (positive control)  
10 to CN (negative control) signal ratio;

- figure 2 represents a comparative study of the detection of sheep PrP<sup>res</sup> using a conventional "sandwich" assay (BAR-224/SAF-34) or with the plasminogen/BAR224 couple;

15 - figure 3 represents a comparative study of the assaying of PrP<sup>res</sup> from a sheep suffering from scrapie, using the technique described in international application WO 99/41280 or the method according to the invention: plasminogen/BAR224 sandwich assay on a  
20 microtitration plate;

- figure 4 represents a comparative study of the direct assaying (invention) and of the indirect assaying (method according to international application WO 01/23425) of PrP<sup>res</sup> from a sheep suffering from  
25 scrapie: comparison of the conditions for capture by plasminogen immobilized on magnetic beads according to the invention or according to international application WO 01/23425;

- figure 5 illustrates the comparison of the  
30 detection of PrP<sup>res</sup> using the technique consisting in preparing SAFs followed by immunometric assay (international PCT application WO 99/41280) with that using PrP<sup>res</sup> capture on beads coupled to plasminogen followed by a direct assay (invention);

35 - figure 6 represents the effect of the dilution of a homogenate of brain from a sheep suffering from scrapie on the detection of PrP<sup>res</sup> by direct assaying on plasminogen coupled to magnetic beads;

- 17 -

- figure 7 represents dilution curves for brain from mice, cows and humans suffering from a TSSE. It illustrates the ability of the method according to the invention to provide a diagnosis for all the TSSEs.

5 **EXAMPLE 1: Method of detection according to the invention: optimization of various parameters**

**1. Coupling of plasminogen to a Covalink NH solid support**

10 The plasminogen is immobilized covalently at the surface of Covalink NH microtitration plates (Nunc) using a homobifunctional coupling agent, disuccinimidyl suberate (DSS). 100  $\mu$ l of a DSS solution (12.5 mg of DSS dissolved in 50 ml of DMSO and 50 ml of 50 mM carbonate buffer pH 9.5) are incubated at the surface  
15 of the Covalink NH wells for 1 hour at ambient temperature.

The wells are washed 3 times with distilled water, and then 100  $\mu$ l of a 2.5  $\mu$ g/ml plasminogen solution in 50 mM carbonate buffer, pH 9.5, are  
20 incubated at the surface of the wells overnight at ambient temperature. The wells are emptied and saturated with EIA buffer (0.1 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, 0.1% BSA and 0.01% sodium azide).

25 **2. Preparation of the sample (step (a) of the method) and capture of PrP<sup>res</sup> on the Covalink NH microtitration plates containing the plasminogen (step (b) of the method)**

30 **A. Conditions for preparing the sample with a view to capture**

25  $\mu$ l of a homogenate of brain from a sheep suffering from scrapie (CP = positive control) or a normal sheep (CN = negative control) are incubated with  
35 225  $\mu$ l of EIA buffer, pH 7.4, comprising an ionic surfactant and proteinase K at a final concentration of 1  $\mu$ g/ml, for 10 minutes at 37°C, and then 10  $\mu$ l of 100 mM Pefabloc<sup>TM</sup> (protease inhibitor corresponding to [4-(2-aminoethyl)benzenesulfonyl] fluoride HCl) are added. 100  $\mu$ l of sample are deposited in the wells of

- 18 -

the Covalink NH microtitration plate containing the plasminogen, and are incubated for 2 hours at ambient temperature.

5     B. Effect of surfactants on the capture of  
PrP<sup>res</sup> by the plasminogen immobilized on a Covalink NH  
solid support

10     Table I below illustrates the results obtained using the BAR-224 antibody to detect the PrP<sup>res</sup> associated with the plasminogen after controlled denaturation by treatment with guanidine/HCl.

15     This table I describes the conditions tested on the capture of PrP<sup>res</sup> by the plasminogen; this table gives details of the effect of various surfactants: Sarkosyl = SK, Triton X100 = T, NP40 = Nonidet P40, Tween 20 = Tween and sodium dodecyl sulfate = SDS.

- 19 -

Table I: Effect of detergents on the capture of PrP<sup>res</sup>  
of brain from a sheep suffering from scrapie by  
plasminogen immobilized on a Covalink NH microtitration  
plate solid support

Incubation buffer composition	CN	CP	CP/CN
EIA buffer + 0.5% SK	0.066	2.435	37.17
EIA buffer + 0.5% SK + 0.5% T	0.054	1.857	34.38
EIA buffer + 0.5% SK + 1% T	0.006	0.837	139.42
EIA buffer + 0.5% SK + 2% T	0.000	0.550	-
EIA buffer + 1% SK	0.035	1.671	48.42
EIA buffer + 1% SK + 0.5% T	0.079	1.942	24.58
EIA buffer + 1% SK + 1% T	0.097	1.997	20.58
EIA buffer + 1% SK + 2% T	0.003	0.851	340.20
EIA buffer + 1.5% SK	0.020	1.428	71.40
EIA buffer + 1.5% SK + 0.5% T	0.103	1.725	16.82
EIA buffer + 1.5% SK + 1% T	0.062	1.976	32.13
EIA buffer + 2% SK	0.003	0.804	267.83
EIA buffer + 2% SK + 0.5% T	0.022	1.430	66.49
EIA buffer + 2% SK + 1% T	0.026	1.731	67.88
EIA buffer + 2% SK + 2% T	* 0.037	1.88	50.81
EIA buffer + 1% T	0.000	0.027	-
EIA buffer + 2% T	0.000	0.354	-
EIA buffer + 4% T	0.006	0.936	170.18
EIA buffer + 10% T	* 0	1.018	-
EIA buffer + 15% T	* 0	0.305	-
EIA buffer + 0.5% SDS	0.017	0.095	5.59
EIA buffer + 1% SDS	0.000	0.008	-
EIA buffer + 3% NP40	0.001	0.779	779.00
EIA buffer + 3% NP40 + 3% Tween	0.000	0.905	-
EIA buffer + 6% NP40	0.013	0.801	64.08
PBS + 3% NP40 + 3% Tween	□ 0.004	0.526	150.29
EIA buffer + 1% DOC	* 0.03	0.014	0.47
EIA buffer + 1% SK + DOC	0.011	0.974	88.55

5 \*: Results obtained in a different experiment and  
standardized relative to the result obtained with the  
EIA buffer + 1% SK

□: Conditions of international application WO 01/23425  
used for the capture of PrP<sup>res</sup> by plasminogen.

10 CN: Negative control

- 20 -

CP: Positive control

EIA buffer: 0.1 M phosphate buffer, pH 7.4 + 0.15 M NaCl + 0.1% BSA + 0.01% sodium azide.

5 The capture conditions selected for the remainder of the assays are: EIA buffer + 1% SK, even though, in table I above, other conditions give a slightly higher CP/CN ratio, because these conditions provide a high CP-CN differential and because, in other experiments, the results were reversed, the CN values  
10 varying.

In the absence of surfactant, no specific capture is observed (binding of PrP<sup>Sc</sup> is even observed).

15 The best results are obtained using sarkosyl as surfactant.

C. Effects of pH and of NaCl concentration on the capture of PrP<sup>Sc</sup> by plasminogen immobilized on a Covalink NH solid support

20 25  $\mu$ l of a homogenate of brain from a sheep suffering from scrapie or a normal sheep are incubated with 225  $\mu$ l of EIA buffer containing various NaCl concentrations and at various pH values and comprising sarkosyl at a final concentration (w/v) of 1% and proteinase K at a final concentration of 1  $\mu$ g/ml, for  
25 10 minutes at 37°C, and then 10  $\mu$ l of 100 mM Pefabloc<sup>TM</sup> are added. The procedure is then carried out as described previously.

Table II gives the results obtained.

- 21 -

Table II: Effect of pH and of NaCl concentration on the capture of PrP<sup>res</sup> of brain from a sheep suffering from scrapie by plasminogen immobilized on a Covalink NH microtitration plate

5

Incubation buffer composition	CN	CP	CP/CN
EIA buffer pH 6 + 0.15 M NaCl + 1% SK	0.032	0.515	16.33
EIA buffer pH 6 + 0.3 M NaCl + 1% SK *	0.033	0.559	16.94
EIA buffer pH 6 + 0.5 M NaCl + 1% SK *	0.058	0.499	8.60
EIA buffer pH 6 + 0.8 M NaCl + 1% SK *	0.168	0.727	4.33
EIA buffer pH 6.5 + 0.15 M NaCl + 1% SK	0.080	0.541	6.76
EIA buffer pH 7 + 0.15 M NaCl + 1% SK	0.090	0.561	6.23
EIA buffer pH 7.4 + 1% SK	0.093	0.454	4.91
EIA buffer pH 8 + 0.15 M NaCl + 1% SK	0.086	0.326	3.78
EIA buffer pH 7.4 + 1% SK	0.068	0.076	1.12
EIA buffer pH 7.4 + 0.5 M NaCl + 1% SK	0.051	0.722	14.15
EIA buffer pH 7.4 + 1 M NaCl + 1% SK	0.100	0.518	5.20

\*: Results obtained in a different experiment and standardized relative to the result obtained with the EIA buffer + 1% SK

10 EIA buffer: 0.1 M phosphate buffer, pH 7.4 + 0.1% BSA + 0.01% sodium azide

The PrP<sup>res</sup> capture conditions preferably selected are as follows: EIA buffer + 0.5 M NaCl + 1% SK.

15 D. Effect of proteinase K concentration on the CP/CN ratio

25  $\mu$ l of a homogenate of brain from a sheep suffering from scrapie or a normal sheep are incubated with 225  $\mu$ l of EIA buffer, pH 7.4, comprising 0.5 M NaCl, a final concentration of 1% of sarkosyl and proteinase K at various concentrations, 0, 0.5, 1, 2, 4 and 8  $\mu$ g/ml final concentration, for 10 minutes at 37°C, and then 10  $\mu$ l of 100 mM Pefabloc<sup>TM</sup> are added. The procedure is then carried out as previously described.

25 Table III and figure 1 give the results obtained.

- 22 -

**Table III: Optimization of the proteinase K (PK)  
concentration**

PK concentration in $\mu\text{g/ml}$	CN	CP	CP/CN
0	0.133	1.107	8.32
0.5	0.178	1.521	10.79
1	0.240	2.125	8.87
2	0.162	2.064	12.74
4	0.108	1.871	17.40
8	0.103	1.661	16.20

These results show that PK at low concentration (2 to 4  $\mu\text{g/ml}$ ) improves the CP/CN ratio, while at the same time conserving a good CP signal.

**3. Controlled denaturation of  $\text{PrP}^{\text{res}}$ , under conditions where the plasminogen/ $\text{PrP}^{\text{res}}$  complex is not dissociated**

**A. Preferred denaturation conditions**

After reaction for 2 hours at ambient temperature, the wells are washed and then incubated with 100  $\mu\text{l}$  of guanidine/HCl, 8 M, for 30 min at 37°C.

**B. Effect of the denaturing agent used after capture and before detection of  $\text{PrP}^{\text{res}}$ , with a labeled antibody**

25  $\mu\text{l}$  of a homogenate of brain from a sheep suffering from scrapie and a normal sheep are incubated with 225  $\mu\text{l}$  of EIA buffer, pH 7.4, comprising 0.5 M NaCl, 1% of sarkosyl and proteinase K at a final concentration of 1  $\mu\text{g/ml}$ , for 10 minutes at 37°C, and then 10  $\mu\text{l}$  of 100 mM Pefabloc<sup>TM</sup> are added. 100  $\mu\text{l}$  are deposited in the wells of a microtitration plate containing immobilized plasminogen.

After reaction for 2 hours at ambient temperature, the wells are washed and then incubated with 100  $\mu\text{l}$  of various denaturing agents for 30 min at 37°C.

The wells are again washed and then incubated with a tracer antibody, BAR224 at 5 Ellman units/ml, for 2 hours at ambient temperature.

After washing, 200  $\mu\text{l}$  of a visualizing solution (Ellman's reagent) are added. The absorbance at 414 nm

- 23 -

of the wells is measured after reaction for 30 min.

Table IV gives the results obtained.

**Table IV: Effect of the denaturing agent used after capture and before detection of sheep PrP<sup>res</sup> with a labeled antibody**

5

Denaturing agents		CN	CP	CP/CN
Urea 2 M		0.056	0.082	1.46
Urea 4 M		0.055	0.116	2.11
Urea 8 M		0.056	0.295	5.27
Guanidine/HCl 2 M		0.108	0.12	1.11
Guanidine/HCl 4 M		0.083	0.2	2.41
Guanidine/HCl 8 M		0.122	1.445	11.84
NaSCN 2 M		0.118	0.09	0.76
NaSCN 4 M		0.054	0.103	1.91
NaSCN 8 M		0.025	0.918	36.72
Guanidine/SCN 2 M	*	0.072	0.347	4.82
Guanidine/SCN 4 M	*	0.024	0.394	16.42
Guanidine/SCN 6 M	*	0.016	0.881	55.06
NaNO <sub>3</sub> 2 M		0.103	0.097	0.94
NaNO <sub>3</sub> 4 M		0.084	0.09	1.07
NaOH 1 M		0.038	0.01	0.26
NaOH 0.5 M		0.023	0.074	3.22
NaOH 0.1 M		0.031	0.175	5.65
HCl 1 M		0.092	0.125	1.36
HCl 0.5 M		0.079	0.136	1.72
HCl 0.1 M		0.057	0.071	1.25
NaCl 2 M		0.085	0.07	0.82
NaCl 4 M		0.063	0.064	1.02
50% HFIP		0.026	0.309	11.88
Methanol		0.021	0.027	1.29
Isopropanol		0.059	0.049	0.83
Ethanol		0.042	0.035	0.83
50% Acetonitrile		0.02	0.023	1.15
50% DMSO		0.014	0.02	1.43
0.5% SDS		0.003	-0.006	-
1% SDS		0.001	0	0.00
5% SDS		-0.004	-0.007	1.75
10% SDS		-0.008	-0.009	1.13

Denaturing agents	CN	CP	CP/CN
5% DOC	0.088	0.09	1.02
10% DOC	0.107	0.094	0.88
20% TX-100	0.021	0.021	1.00
5% SK	-0.011	-0.012	1.09
10% SK	0.011	-0.013	-
20% SK	0.019	0.005	0.26
2% CHAPS	0.014	0.012	0.86
0.1 M citrate buffer, pH 3.5	0.017	0.022	1.29
0.1 M glycine buffer, pH 3.5	0.013	-0.001	-
10% HFIP	-0.004	-0.002	0.50
EIA buffer	0.016	-0.005	-

\*: Results obtained with a different experiment and standardized relative to the result obtained with the EIA buffer + 1% SK

Only certain conditions tested give a good CP signal: it is always strong chaotropic agents which give good detection of PrP<sup>res</sup>, such as urea, guanidine hydrochloride, guanidine thiocyanate and sodium thiocyanate.

#### 4. Detection of PrP<sup>res</sup> complexed with plasminogen directly on the solid support: selection of the visualizing antibody

The procedure is carried out as described in point 3., using 8 M guanidine/HCl as denaturing agent.

Eight antibodies were tested at a concentration of 5 Ellman units/ml: SAF34, SAF53, SAF61, 8G8, BAR221, BAR224, BAR231 and BAR233.

Table V gives the results obtained.

- 25 -

**Table V: Selection of the tracer antibody for detecting  
sheep PrP<sup>res</sup>**

Tracer	CN	CP	CP/CN
SAF34	0.082	2.163	26.37
SAF53	0.381	2.285	6.01
SAF61	0.372	2.385	6.41
8G8	0.160	1.014	6.36
BAR221	0.039	1.133	29.04
BAR224	0.015	2.121	146.24
BAR231	0.020	0.153	7.85
BAR233	0.042	0.767	25.98

5 The tracer antibody BAR224 gives the best CP/CN ratio and also a good CP signal for detecting sheep PrP<sup>res</sup>.

**EXAMPLE 2: Comparative study of the detection of sheep PrP<sup>res</sup> using a conventional "sandwich" assay**  
10 (BAR224/SAF34) or with the plasminogen/BAR224 couple

This study made it possible to compare the detection sensitivity of the two types of sandwich. A preparation of PrP<sup>res</sup> (SAF) was obtained from a brain of a sheep suffering from scrapie:

15 - For the BAR224/SAF34 sandwich assay: the SAF preparations (according to the rapid SAF protocol as described in international PCT application WO 99/41280) from 250  $\mu$ l of homogenate of brain from a sheep suffering from scrapie or a normal sheep are taken up  
20 and denatured with 25  $\mu$ l of a denaturing buffer (buffer C, as defined in international PCT application WO 99/41280) for 10 min at 100°C. The pellets are taken up with 250  $\mu$ l of EIA buffer and diluted successively in EIA buffer. The dilutions are deposited in the wells  
25 of a microtitration plate containing the BAR224 antibody. After reaction for 2 hours at ambient temperature, the wells are washed and then incubated with 100  $\mu$ l of the SAF34 tracer antibody (at 5 EU/ml) for 2 hours at ambient temperature. After washing,

- 26 -

200  $\mu$ l of the visualizing solution are added. The absorbance at 414 nm is measured after reaction for 30 minutes.

- For the plasminogen/BAR224 sandwich assay:  
5 the SAF preparations (identical to above) are taken up with 250  $\mu$ l of EIA buffer containing a final concentration of 4 mM Pefabloc<sup>TM</sup>, and then treated by ultrasound until the pellet has dissolved. Successive dilutions are then carried out in EIA buffer comprising  
10 Pefabloc<sup>TM</sup>. The dilutions are deposited onto a solid support (microtitration plate) containing plasminogen. After incubation for 2 hours at ambient temperature, the wells are washed; after the washing step, the PrP<sup>res</sup> is denatured in a controlled manner with guanidine/HCl  
15 (8 M, 30 minutes at 37°C), and the various wells are then incubated with 100  $\mu$ l of the BAR224 tracer antibody (at 5 EU/ml) for 2 hours at ambient temperature. After washing, 200  $\mu$ l of visualizing  
20 solution are added. The absorbance at 414 nm is measured after reaction for 30 minutes.

Figure 2 gives the results obtained and shows that the two systems exhibit a comparable sensitivity with a slight advantage for the entirely immunological assay.

25 **EXAMPLE 3:** Comparative study of the assaying of PrP<sup>res</sup> from a sheep suffering from scrapie using the technique according to international PCT application WO 99/41280 and the plasminogen/BAR224 sandwich assay on a micro-titration plate, according to the invention

30 In this second experiment, the sensitivity of the two methods are compared while including, for the method according to application WO 99/41280, the SAF preparation technique and, for the plasminogen technique, the dilution that must be carried out before  
35 capture, in particular so as to obtain a protein concentration in the homogenate of 20 mg/ml (2% w/v).

A homogenate containing 20% of brain from a sheep suffering from scrapie is diluted in a normal sheep brain homogenate (1/5, 1/10, 1/20, 1/40, 1/80,

- 27 -

1/160 and 1/320 dilution) or is not diluted.

In the case of the test according to international application WO 99/41280, the SAFs are prepared from 250  $\mu$ l of homogenate. For the detection part, the BAR224 and SAF34 antibodies are used as capture antibody and tracer antibody, respectively.

In the case of the test according to the invention:

. the plasminogen is immobilized on the micro-titration plates as specified in example 1;

. the assay is carried out with 25  $\mu$ l of homogenate, using, as capture buffer, EIA buffer comprising 0.5 M NaCl, 1% of sarkosyl and 2.5  $\mu$ g/ml of proteinase K, 8M guanidine/HCl as denaturing agent, and BAR224 as tracer antibody.

The results are given in figure 3 and show that the test according to international PCT application WO 99/41280 has a very clear advantage in terms of sensitivity because it processes 250  $\mu$ l of 20% homogenate, i.e. 50 mg of brain tissue, instead of 25  $\mu$ l of the same 20% homogenate, i.e. 5 mg, for the test according to the invention. This disadvantage is the result of the use of microtitration plates, because the volume of 2% homogenate processed is limited (a maximum of 300  $\mu$ l). However, this disadvantage disappears when magnetic beads, which make it possible to process very large volumes (at least 50 ml) are used.

**EXAMPLE 4:** Comparative study of the direct assay according to the invention with an indirect assay of PrP<sup>res</sup> from a sheep suffering from scrapie, attached to plasminogen immobilized on magnetic beads. Comparison with the capture conditions used in international application WO 99/41280

- 100  $\mu$ g of plasminogen were coupled to 1 ml of magnetic beads (Dynal M-280) according to the method described by the manufacturer.

- 25  $\mu$ l of a homogenate containing 20% of brain from a sheep suffering from scrapie or a normal sheep

- 23 -

are incubated:

(1) either with 225  $\mu$ l of capture buffer, as described above,

(2) or with 225  $\mu$ l of PBS comprising 3% of NP-40 and 3% of Tween-20 (conditions described in international PCT application WO 01/23425).

- 10  $\mu$ l of beads, coupled to plasminogen, are added to each sample and then incubated for 2 hours at ambient temperature with rotation. The beads are washed 3 times:

. either (1) with EIA buffer comprising 1% of Tween 20,

. or (2) with PBS comprising 2% of NP-40 and 2% of Tween 20.

After a wash with PBS, 30  $\mu$ l of 6M guanidine/HCl are added for the direct assay and 30  $\mu$ l of 6M urea and 0.25% sarkosyl are added for the indirect assay, then incubation is carried out for 10 minutes at 100°C.

The results are given in figure 4:

. In the case of the direct assay, after the denaturation step, the plasminogen-coupled beads are washed and then incubated with 500  $\mu$ l of BAR224 tracer in EIA buffer/1% Tween 20 (at 5 EU/ml) for 2 hours at ambient temperature with agitation. The beads are then washed twice with EIA buffer/1% Tween 20 and once with PBS, before adding 600  $\mu$ l of Ellman's reagent. After reaction for 30 minutes, 200  $\mu$ l of reaction medium are removed and the absorbance at 412 nm is measured.

. In the case of the indirect assay, after the denaturation step, the denatured PrP eluted from the plasminogen is taken up with 300  $\mu$ l of EIA buffer and measured using a BAR224/SA524 "sandwich" assay.

It emerges from this example that the capture conditions according to the present invention make it possible to obtain results that are significantly superior to those obtained with the capture conditions of international application WO 01/23425. It will also be noted that the direct assay, which is simpler, is also more sensitive.

- 29 -

**EXAMPLE 5:** Comparison of the detection of PrP<sup>res</sup> using the SAF preparation technique followed by an immuno-metric assay (method according to international application WO 99/41280) with that using the capture of PrP<sup>res</sup> on plasminogen-coupled beads followed by a direct assay

In the case of the PrP<sup>res</sup> assay according to the method described in international PCT application WO 99/41280, the SAFs are prepared from 500  $\mu$ l of homogenate containing 20% of brain from a normal sheep or a sheep suffering from scrapie (diluted 1/10, 1/50 and 1/100 in a normal sheep brain homogenate, or not diluted). The SAF pellets are taken up and denatured with 50  $\mu$ l of denaturing buffer (buffer C, as defined in international PCT application WO 99/41280) for 10 minutes at 100°C. The amount of PrP is then measured with the BIO-RAD Platelia<sup>®</sup> BSE detection kit (ref. 51103) (immunoenzyme kit for in vitro detection of PrP<sup>res</sup> after purification according to the method described in international PCT application WO 99/41280).

In the case of the assay using plasminogen coupled to magnetic beads, the 500  $\mu$ l of homogenate (the same as above) are diluted 10 times in EIA buffer comprising 0.5 M NaCl and 1% of sarkosyl, and then incubated with 30  $\mu$ l of beads containing the immobilized plasminogen for 3 hours at ambient temperature. After washing, a controlled denaturation is carried out by treatment with a guanidine/HCl solution for 10 minutes at 100°C. After 3 washes with EIA buffer/1% Tween 20 and one wash with PBS, the beads are incubated with the BAE224 tracer in EIA buffer for 2 hours at ambient temperature. The beads are again washed 3 times with EIA buffer/1% Tween 20 and once with PBS before adding the visualizing solution (Ellman's reagent).

The results are given in figure 5, which shows that the plasminogen technique appears to be at least as sensitive as the test according to international PCT

application WO 99/41280. The use of magnetic beads makes it possible to work with a larger volume and to compensate for the disadvantage associated with the need to dilute the homogenate before capture with the plasminogen.

**EXAMPLE 6:** Effect of the dilution of a homogenate of brain from a sheep suffering from scrapie on the detection of PrP<sup>res</sup> by direct assay on plasminogen coupled to magnetic beads. Demonstration of the ability of the method to concentrate PrP<sup>res</sup> diluted in a large volume of sample

500  $\mu$ l of a homogenate of brain from a sheep suffering from scrapie are diluted in 5, 10, 20 and 50 ml of EIA buffer, pH 7.4, comprising 0.5 M NaCl and 1% of sarkosyl, and then incubated with 30  $\mu$ l of plasminogen-coupled beads for 4 hours at ambient temperature. The procedure is then carried out as described above.

The results are given in figure 6, which shows the ability of the method according to the invention to concentrate dilute PrP<sup>res</sup>.

**EXAMPLE 7:** Application of the invention to the detection of PrP<sup>res</sup> in homogenates of brains from mice, cows and humans suffering from a TSSE

Homogenates at 20% (w/v) obtained from a brain of a mouse (infected with a sheep scrapie strain) or from a brain from a bovine (infected with BSE) or from a human brain (infected with Creutzfeldt-Jakob disease) were diluted to a concentration of 1% (w/v) in the capture buffer (EIA buffer comprising 0.5 M NaCl and 1% (v/v) sarkosyl, final concentration). These homogenates were then brought into contact with magnetic beads containing immobilized plasminogen, and analyzed under the conditions described in example 4.

More precisely, 850  $\mu$ l of EIA buffer/0.5 M NaCl + 50  $\mu$ l of 10% SK + 10  $\mu$ l of plasminogen-coupled magnetic beads are added to 50  $\mu$ l of a negative or positive control brain homogenate (diluted in a negative homogenate + 50  $\mu$ l of 10% SK, or not diluted);

- 21 -

incubation is carried out for 2 hours 30 min at ambient temperature with rotation; the beads are then washed 3 times with EIA buffer comprising 1% of Tween 20, and then once with PBS. The controlled denaturation is

5 carried out in the presence of 50  $\mu$ l of 4M guanidine thiocyanate (Gn/SCN) at 100°C for 8 min. After the denaturation step, the beads are washed in PBS and then incubated with 500  $\mu$ l of tracer antibody for 2 h at ambient temperature, with agitation (at 5 EU/ml). The

10 beads are then washed twice with EIA buffer/1% Tween 20 and once with PBS, before adding 1 ml of Ellman's reagent. After reaction for 20 min, 200  $\mu$ l of reaction medium are removed and the absorbance at 412 nm is measured.

15 This experiment (figure 7) shows that the test described functions with species other than sheep and can detect prion strains other than scrapie strains.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**